This is an outdated version published on 09-01-2022. Read the most recent version.

Quality Control Study of Different Products from Famotidine Tablets in the Iraqi Market

Authors

DOI:

https://doi.org/10.17533/udea.vitae.v29n1a347467

Keywords:

Generic, Drug, Famosam, Famodin, Release kinetics

Abstract

Background: In developing countries, particularly in Iraq, the use of generic medicines has been increasing in recent years, primarily as a cost-saving measure in healthcare provision. In the Iraqi market, famotidine tablets are available from different pharmaceutical companies. As a result, regular pre-marketing quality testing is required to check the quality and identify which product might safely substitute the innovator product in the event of the innovator brand's unavailability or high cost.

Objective: various quality control tests have been conducted to determine the Pharmaceutical Equivalence of the different generic and brands of Famotidine film-coated tablets marketed in Iraq.

Materials and Methods: Four different samples of the most commonly available Famotidine 20 mg tablets in the Iraqi market were tested for drug contents, friability, and hardness. Additionally, the in-vitro drug release and kinetics were evaluated.

Results: slight differences in the products’ content were found; however, they were within the acceptable requirement of British Pharmacopeia (BP) and The United States Pharmacopoeia (USP) 30, NF 25. Similarly, the friability and hardness were within the excellent range according to the B.P. and USP. The results of our study indicated that the tested brand (Famodin) and the three generic products (Famosam, Ulceran, and Famodar) of Famotidine tablets have a unique pattern of in-vitro release profiles. However, all the tested brands and generic pills complied with the USP specifications for the immediate release dosage forms except for Famosam. Release kinetic for the four tested products indicates first-order kinetic models.

Conclusion: The findings revealed that nearly all of the tested Famotidine tablet brands and generics met the pharmacopeial requirements for oral tablets. As a result, if acquiring the innovative brand of famotidine tablets is difficult to obtain, healthcare providers may be advised to use the tested products instead.

|Abstract
= 905 veces | PDF
= 461 veces|

Downloads

Download data is not yet available.

References

- Martindale, Sweetman. S.C: The Complete Drug Reference; Thirty-sixth edition 2009:1730-1731. DOI: https://dx.doi.org/10.3163%2F1536-5050.100.1.018

- British national formally, edit 80, 2021;223, BNF 80 pdf free download (British National Formulary September 2020 - March 2021) - Pharmaceuticals Industry - Web of Pharma

- Muhammad A, Humaira N, Madeeha M. Post Market In-vitro Bioequivalence Study on Representative Brands of Ciprofloxacin Tablets (500 mg) Prescribed in Typhoid Disease. AJPS 2014, 2(5):8-11. DOI: https://dx.doi.org/10.12691/ajps-2-5B-3.

- Mus'ab M. K, Hiyam A.T, ImadT: Comparative evaluation of different marketed products of ciprofloxacin tablets in vitro, Iraq J Pharm; 2010;9-10(1):9-15, DOI: https://dx.doi.org/10.33899/iphr.2010.49978

- Saad M.M, Mohammed K.S, Radhwan N.Z: Quality control study on Conventional Metronidazole tablets available in the Iraqi market, Research J. Pharm. and Tech. 2021;14(2): 803-808, DOI: https://dx.doi.org/10.5958/0974-360X.2021.00141.4

- José RM, Dulce KS, Marcela H, Alma RC, Adriana MD.Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system. Saudi Pharm J. 2014; 22(2): 141–147, DOI: https://dx.doi.org/10.1016/j.jsps.2013.02.001

- Adegbolagun OA., Olalade OA., Osumah SE. Comparative evaluation of the biopharmaceutical and chemical equivalence of some commercially available brands of ciprofloxacin hydrochloride tablets. Trop. J. Pharm. Res. 2007; 6:737-745. DOI: https://dx.doi.org/10.4314/tjpr.v6i3.14654

- The United States Pharmacopoeia (USP) 30, NF 25. The United States Pharmacopeial Convention Inc.: USA, 2006. p2110. https://www.abebooks.com/servlet/BookDetailsPL?bi=30961907586&cm_ven=sws&cm_cat=sws&cm_pla=sws&cm_ite=30961907586&clickid=QJ33KIxw-xyIUlVxIw0gnRHAUkBT6z30tX-S0g0&cm_mmc=aff-_-ir-_-353196-_-77798&ref=imprad353196&afn_sr=impact

- Zeenath S, Gannu. R, Bandari S and Rao YM: Development of gastroretentive systems for Famotidine: in vitro Characterization; Acta Pharmaceutica Sciencia; 2010; 52: 495-504, DOI: https://dx.doi.org/10.4314/tjpr.v12i6.1

- Allen LV, Popovich NG., Ansel HC. Ansel's pharmaceutical dosage forms and drug delivery system. 10th edition; 2014: 271-272. In: Lippin Cott Williams and Wilkins, Philadelphia.

- Mona. M. D, Nasr E.H.N, Sozan. Sh.T: Preparation and Evaluation of Novel Extended-Release Trihexyphenidyl Hydrochloride Tablets, J. Adv. Biomed. & Pharm. Sci. 2020;3:89-100, DOI: https://dx.doi.org/10.21608/JABPS.2020.25846.1079

- Shirsath N.R, Jagtap V, Goswami A.K: Formulation and Development of Famotidine Solid Dispersion Tablets for their Solubility Enhancement; Indian Journal of Pharmaceutical Education and Research.2019;53 (4 Suppl): S548-52, DOI: https://dx.doi.org/10.5530/ijper.53.4s.149

- Marwa M.M, Nidhal KM.Preparation and evaluation of famotidine nanosuspension; AJPS, 2018;18(2):13-23, DOI: https://doi.org/10.32947/ajps.18.02.0370

- Shabnam A, Babita K, Kamla P: Development and characterization of controlled release famotidine matrix tablets containing complex; Int J App Pharm,2017; 9(4):38-46, DOI: https://dx.doi.org/10.22159/ijap.2017v9i4.18859

- Zhou Y, Chu JS, Li JX, Wu XY. Theoretical analysis of release kinetics of coated tablets containing constant and non-constant drug reservoirs. International Journal of Pharmaceutics. 2010;385(1–2):98-103, DOI: https://dx.doi.org/10.1016/j.ijpharm.2009.10.039

- Gohel MC, Sarvaiya KG, Mehta NR, Soni CD, Vyas VU, Dave RK. Assessment of similarity factor using different weighting approaches. Diss Technol. 2005; 12:22–37.

- Gurudeeban S, Satyavani K, Ramanathan T, Mohanraj P: Formulation and Evaluation of Tablets from Antidiabetic Alkaloid Glycosin; J. Med. Sci.,2015; 15 (1): 18-24. DOI: https://dx.doi.org/10.3923/jms.2015.18.24

- Arefin P, Ahmed R, Habib MD, Bhattacharjee SC, Chakraborty D, Das S, Karmakar D, Bhowmik D. Evaluation of Critical Quality Attributes of Immediate Release Ciprofloxacin Tablets of Different Pharmaceutical Companies in Bangladesh. Biosci., Biotech. Res. Asia.2020;17(4):781-788. DOI: https://dx.doi.org/10.13005/bbra/2883

- Choudhary N, Avari J. Formulation and evaluation of taste mask pellets of granisetron hydrochloride as an orodispersible tablet. Brazilian Journal of Pharmaceutical Sciences.2015; 51(3):569-578. DOI: https://dx.doi.org/10.1590/S1984-82502015000300009

- Abebe K, Beressa TB, Yimer BT. In-vitro Evaluations of Quality Control Parameters of Paracetamol Tablets Marketed in Gondar City, Northwest Ethiopia. Drug, Healthcare and Patient Safety 2020;12:273-297, DOI: https://dx.doi.org/10.2147/DHPS.S282420

- Albo HarmrahL KT, AL-Shaiban AJ, AL-Edresi SS, AL-Gburi KM. A Comparative study of quality control testing on candesartan cilexetil conventional tablets in Iraq. Int J App Pharm.2020;12(2):103-108, DOI: http://dx.doi.org/10.22159/ijap.2020v12i2.36220

Drug release

Downloads

Published

09-01-2022

Versions

How to Cite

Jassem, N. (2022). Quality Control Study of Different Products from Famotidine Tablets in the Iraqi Market. Vitae, 29(1). https://doi.org/10.17533/udea.vitae.v29n1a347467

Issue

Vol. 29 No. 1 (2022)

Section

Pharmacology and Toxicology

License

Copyright (c) 2022 Nizar Jassem

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright Notice and Open Access Statement

The Journal Vitae works under the Open Access license, and the published manuscripts remain available for the public, both on the Journal's website and in databases, under the Creative Commons license, "Noncommercial Attribution" and "Share alike" systems, adopted in Colombia. Hence, when the authors agree to publish in the Journal Vitae, they will not have the right to economic retributions on publications and reproductions through different diffusion media. The documents are freely available to the internet public, permitting users to read, download, copy, distribute, print, search, or link to the full texts and pass them as data to software. The only constraint on reproduction and distribution, should be to give authors control over the integrity of their work and the right to be appropriately acknowledged and cited.

Authors declare that:

  1. They are the intellectual property owners and are responsible for all the information stated in the article.

  2. This manuscript has not been submitted or published in other printed or digital media. They accept the responsibility for the judgments, opinions, and points of view expressed in the published article and, therefore, they exonerate Universidad de Antioquia and Journal Vitae from any process.

  3. They exempt Universidad de Antioquia and Journal Vitae from settling conflicts or disputes related to the authorship of the referred article.

  4. They accept the revision of the original manuscript by suitable personnel, and they bind themselves to perform the corrections appointed or suggested by the assessors.

  5. Therefore, they know the editorial process and will not bind the Editorial Board of the Journal to assume any obligations regarding the volume and issue in which the article is published.

  6. They transfer the rights of publication, reprinting, and distribution of the article from the moment of its approval, in print and digital format, without the right to economic rewards, and under the licensing conditions considered relevant by Journal Vitae.

  7. They fully authorize Universidad de Antioquia and Journal Vitae to submit the published material to the diverse databases and indexing systems where the Journal can be found to comply with the requirements of the regulatory authorities to maintain the national classification of journals.

  8. They will assume the article publication costs established for the current issue, and they will make the payment as soon as they are informed about the volume and the issue in which the final version of the article is published.

  9. After the article is published, you can share digital or printed copies in a noncommercial manner. You will be able to use the paper in your institution or company for educational or research purposes, including the use in course programs.

Conflict of interest: Authors are responsible for recognizing and disclosing any financial or other benefits that could be perceived to bias their work, acknowledging all financial support and any personal connections with potential sponsors. Examples of such conflicts include receiving research funds or honoraria, serving on advisory boards, stock ownership, or employment and consulting arrangements. Authors without such connections should clearly state that they have no financial support or personal relationships that could be perceived to bias their work. All conflicts of interest should be disclosed on the author's identification page of the manuscript.

Crossref
Scopus
Google Scholar
Europe PMC